A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer (Q34433349)

2 August 2017

A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer (English)

1 reference

2 August 2017

1 reference

3

George Wilding

1 reference

2 August 2017

William R Schelman

1

1 reference

2 August 2017

Glenn Liu

2

1 reference

2 August 2017

Thomas Morris

4

1 reference

2 August 2017

De Phung

5

1 reference

2 August 2017

Robert Dreicer

6

1 reference

2 August 2017

19 September 2009

1 reference

Investigational New Drugs

2 August 2017

1 reference

2 August 2017

29

1 reference

2 August 2017

1

1 reference

2 August 2017

118-125

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-009-9318-5

2 August 2017

0 references

cites work

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Endothelin-1 promotes cell survival in renal cell carcinoma through the ET(A) receptor

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

The endothelin axis: emerging role in cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Endothelin-1 from prostate cancer cells is enhanced by bone contact which blocks osteoclastic bone resorption

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Enhanced endothelin ET(B) receptor down-regulation in human tumor cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Endothelins in health and disease: an overview

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Binding and functional properties of endothelin receptor subtypes in the human prostate

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3008512

Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression

27 October 2018

1 reference

12 December 2020

Localization of endothelin receptors in the human prostate

1 reference

12 December 2020

Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 tria

1 reference

12 December 2020

Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells

1 reference

12 December 2020

Endothelins as autocrine regulators of tumor cell growth

1 reference

12 December 2020

Massive amounts of immunoreactive endothelin in human seminal fluid

1 reference

12 December 2020

Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade

1 reference

12 December 2020

1 reference

12 December 2020

10.1007/S10637-009-9318-5

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference